SLS Venture
VC Fund
Stockholm, Sweden
SLS Venture is a VC fund in Stockholm focused on Health Care and Biotechnology. SLS Venture, a Scandinavian-based venture capital company, is the result of the merger of the life science team from The Sixth Swedish National Pension Fund, Medicon Valley Capital and Innoventus. The fund is one of the largest investment funds in Scandinavia in the life science sector with approx. € 270 M (USD 325 M) under management.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries SLS Venture invests in
Stages SLS Venture invests in
Countries SLS Venture invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series C
- $6.3M–$15M
Investment Focus
Industry
- Health Care 6 (100%)
- Biotechnology 6 (100%)
- Medical 3 (50%)
- Pharmaceutical 2 (33%)
- Health Diagnostics 2 (33%)
Stage
- Series C 2 (33%)
- Funding Round 2 (33%)
- Series A 1 (17%)
- Series B 1 (17%)
Country
- Denmark 3 (50%)
- United States 2 (33%)
- Sweden 1 (17%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Henrik Lawaetz
Partner and Managing Director
|
Partner and Managing Director | Total investments: 0 | Find email | |
Mikael Mortensen
CFO and Partner
|
CFO and Partner | Total investments: 0 | Find email | |
Per Carendi
Partner and CEO
|
Partner and CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Action Pharma A/S operates as a research and development focused biotechnology company. It discovers and develops new drugs and treatment concepts to treat cardiovascular disease and inflammatory diseases, as well as metabolic diseases, such as type-II diabetes and obesity. The company's product pipeline includes AP214, a modifiedÃMSH-peptide analogue for the treatment of post-surgical kidney injury associated with cardiac surgery; and AP1030 and AP11 series, oral anti-diabetic (OAD) for the treatment of type-II diabetes associated with overweight/obesity. Its product pipeline also comprise AP1189, an oral anti-inflammatory compound for the treatment of inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis; and AP405, a modified MSH peptide analogue for the treatment of inflammatory skin diseases, such as atopic dermatitis. The company was founded in 2000 and is based in Holte, Denmark. | $6.3M / Series C / Jul 16, 2010 | ||
| AdvanDx is a leading provider of rapid and accurate molecular diagnostic tests for the identification of pathogens causing critical infections in hospitalized patients. Its mission is to help healthcare providers optimize antibiotic therapy earlier in order to improve patient outcomes while limiting unnecessary antibiotic use and reducing hospitalcosts.AdvanDx was founded in 2002 and headquartered in Woburn, Massachusetts. | $15M / Series C / Sep 18, 2007 | ||
| OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera’s intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria, and enzymes. Oxabact® holds Orphan Drug designations in Europe and in the US for thetreatment of primary hyperoxaluria. | $14.5M / Jun 29, 2007 | ||
| Light Sciences Oncology develops cancer and tumor treatment drugs. Additionally, it offers oncology drugs research and development services to treat hepatocellular carcinoma, metastatic colorectal cancer, and glioma. Light Sciences Oncology was founded in 1994 and is headquartered in Bellevue, Washington. | $32M / Series A / Dec 14, 2005 | ||
| Exiqon operates in two business areas: Life Sciences and Diagnostics. Exiqon Life Sciences, a leading provider of flexible solutions for RNA analysis. Exiqon’s research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and thedevelopment of cancer and other diseases. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions based on the tools developed by Exiqon Life Sciences. | $20M / Jun 03, 2005 | ||
| Nuevolution is a leading small molecule lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics®, a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based drug discovery technology. Chemetics® enables rapid synthesis andDNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented quantity, quality and speed compared to existing drug discovery technologies. Nuevolutions library collection currently exceeds 1 billion small molecule compounds and synthetic biologics for screening. Nuevolution partners its technology with pharmaceutical and biotechnology companies. Nuevolution has entered into agreementswith Merck & Co., Lexicon Pharmaceuticals, GlaxoSmithKline, Novartis Pharma and Boehringer Ingelheim. Nuevolution has also entered into a joint venture consortium between Nuevolution, EpiTherapeutics, ExpreS2ion Biotechnologies and Professor Kristian Helin (Biotech Research & Innovation Centre, University of Copenhagen) aiming at discovery and development of novel small molecule drugs against epigenetic factors. This $ 4 million budget project is supported by the Danish High Technology Fund. Nuevolution has demonstrated the power of Chemetics® by identifying highly potent and drug like novel ligands with the potential toaddress major unmet medical needs across a range of therapeutic areas and target classes. Nuevolution is a privately owned company by key Scandinavian investors, including Industrifonden, SEB Venture Capital, SunstoneCapital, SLS Invest and Novo A/S. | $15M / Series B / Oct 10, 2003 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does SLS Venture invest in?
SLS Venture invests primarily in Health Care, Biotechnology and Medical startups, most often at Series C and Funding Round stage. Most of the 6 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is SLS Venture's check size?
SLS Venture typically joins rounds of $6.3M–$15M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds SLS Venture participates in.
How do I contact SLS Venture?
Public channels for SLS Venture include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at SLS Venture?
The team at SLS Venture includes Henrik Lawaetz (Partner and Managing Director), Mikael Mortensen (CFO and Partner) and Per Carendi (Partner and CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
